aGVHD Clinical Trial - First Line Therapy for High Risk Acute GVHD

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the Treatment of High risk aGVHD(acute graft-versus-host disease )

Clinical Trial Description

Acute graft-versus-host disease (aGVHD) is treated with systemic corticosteroid immunosuppression as first line therapy. Many patients with high risk aGVHD do not respond to primary therapy, high-dose systemic corticosteroids; therefore, survival for those patients remains particularly poor. Here we determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the Treatment of High risk aGVHD. ;

Study Design

Related Conditions & MeSH terms

aGVHD
Stem Cell Transplant Complications

Clinical Trial Details

NCT number	NCT04061876
Study type	Interventional
Source	Chinese PLA General Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	August 25, 2019
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03482154` - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Recruiting	`NCT06080490` - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed	`NCT03042676` - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting	`NCT03871296` - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Not yet recruiting	`NCT06022445` - Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
Recruiting	`NCT04502628` - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT	N/A
Recruiting	`NCT03793517` - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT	Phase 2/Phase 3
Completed	`NCT03454568` - The Patients' Experience After Stem Cell Transplant
Recruiting	`NCT05466201` - The Use of Eltrombopag Post HSCT in BMFS	Phase 2/Phase 3
Not yet recruiting	`NCT04080622` - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.	Phase 3
Recruiting	`NCT05523336` - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed	`NCT03355235` - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed	`NCT04888286` - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Recruiting	`NCT04167683` - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Active, not recruiting	`NCT03967665` - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution	Phase 3
Withdrawn	`NCT05104268` - Study of a New Medical Device for Oral Mucositis	Early Phase 1
Recruiting	`NCT04623424` - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting	`NCT04669210` - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT	Phase 2
Completed	`NCT03489551` - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients	Phase 4
Completed	`NCT04106089` - Sleep in Pediatric HSCT	N/A